What Can You Expect at the Premier Autoimmune Neuromuscular & Nerve Disorders Forum in 2026?
The Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit is your opportunity to step inside one of the fastest-evolving areas in biopharma and engage directly with the leaders shaping its future. Over three days, you’ll gain a deep, mechanism-driven understanding of diseases like Myasthenia Gravis, CIDP, GBS and MMN, going beyond surface-level updates to explore the biology, biomarkers and translational challenges defining success.
Expect cutting-edge insights on emerging therapeutic approaches, honest discussions around what’s not working, and practical strategies to differentiate in an increasingly competitive landscape. Through a mix of data-led presentations, interactive roundtables and high-value networking, you’ll leave with the clarity, connections and confidence needed to advance your pipeline and capitalise on this transformative moment in autoimmune neuromuscular drug development.
Unmissable Event Highlights
Rethinking Preclinical Models to Improve Clinical Success
Challenge the limitations of current in vitro and in vivo models across MG, CIDP, GBS and MMN, and uncover how poor disease representation is driving translational failure. Gain practical frameworks to redefine what “good” preclinical evidence looks like and ensure early signals truly predict clinical efficacy.
With Expert Insights from:
Cracking MG Subtypes to Enable Precision Therapies
Dive into the distinct biology of AChR-positive versus MuSK-positive MG to understand how mechanistic differences should shape therapeutic strategy. Learn how aligning drug modality to subtype can improve responder rates and optimise clinical trial design.
With Expert Insights From:
Winning in a Crowded MG Market Through Smarter Positioning
Explore how emerging mechanisms, from FcRn to CAR-, can be strategically positioned in an increasingly saturated landscape. Identify how to differentiate your asset, sequence therapies effectively, and target patients who fail existing treatments.
With Expert Insights From:
Reframing Autoantibodies to Unlock Better Diagnostics & Treatments
Move beyond simply reducing antibody levels to understand their true role in disease. Examine the limitations of “seronegativity,” uncover new autoantibody targets, and refine patient stratification to enable more precise, biology-driven development.
With Expert Insights From:
Redefining CIDP: From Clinical Label to Biological Disease
Interrogate CIDP as a poorly defined syndrome and uncover why heterogeneity is undermining trial success. Discover how biomarker-driven stratification and immunophenotyping can transform trial design and unlock meaningful clinical outcomes.
With Expert Insights From:
Transforming Target Discovery with Better Data & Models
Learn how to overcome flawed discovery systems by integrating multi-omics, AI-driven insights and clinically relevant biomarkers. Improve early target validation and prioritisation to reduce late-stage failure in neuromuscular drug development.
With Expert Insights From:
Explore the Full Event Guide
- 18+ Industry Expert Speakers Shared Groundbreaking Research & Strategies
- 2 Deep Dive Workshops Dissecting Patient Heterogeneity, Precision Therapeutics & the Translational Gap
- Unmissable networking opportunities, including roundtable discussions and a poster session
- Understand the Underlying Biology of Neuromuscular Autoimmune Disease & Peripheral Neuropathies Through an Industry Lens
Attending Companies Include
Explore the Agenda
Uncover how industry leaders are tackling disease biology, biomarkers and translational risk across MG, CIDP, GBS and MMN through data-driven presentations, interactive roundtables and strategic panel discussions.
Partner With Us
Position your solutions at the centre of a rapidly evolving field by engaging directly with biopharma teams seeking to improve models, biomarkers and clinical development strategies.
Join Biopharma Experts
Connect with discovery, translational and clinical experts advancing autoimmune neuromuscular pipelines, and build high-value relationships through focused, peer-driven networking.